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Inflammatory reactions, secondary to pathogenic stimuli, are 
important for the initiation of necessary immune response for 
combating the external stimuli when effectively and efficiently 
deployed. Infection with Plasmodium falciparum, the causative 
agent of malaria, especially common in sub-Saharan Africa,1,2 
is one such pathogen for which the inflammatory cascade 
would be necessary, considering possible infection severity, 
especially in nonimmune travelers or children.3–5 Several innate 
immunity genes have been implicated, at one time or another, 
as having significant roles in disease severity, infection out-
come, or development of possible sequelae, postinfection.6 One 
such gene is CD14, a coreceptor to the toll-like receptor 
(TLR)-4/MD2 complex on leukocytes,7–10 and expressed on 
many cell types. It has been demonstrated to mediate innate 
immune response due to its specificity for bacterial lipopoly-
saccharide and consequent pro-inflammatory signaling and 
initiation of phagocytosis.11–13 It lends its capacity to T-cell 
plasticity, driving a TH1 differentiation, especially with infec-
tions such as malaria.
In published reports, genetic variations leading to dysfunc-
tional monocyte functions have been implicated in disease sus-
ceptibility and outcome, probably clarifying how human 
populations have adapted to major infectious diseases through 
the ages.14 Genetic variants of the CD14 gene (a C-to-T tran-
sition, snp −159 C/T) have been shown to be associated with 
susceptibility to multiple diseases and conditions including 
allergic rhinitis,15 functional dyspepsia,16 inflammatory bowel 
disease,17 gram-negative bacteria, and respiratory infections, 
including brucellosis.18–21 Its significance in allergic reactions 
and outcome in patients with asthma have also been docu-
mented.21,22–24 In human, malaria infections particularly, ele-
vated levels of soluble CD14 have been found in patients with 
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acute infections,25 concluding that soluble CD14 levels may 
play a critical role in disease severity. A murine infection model 
has been the clearest to delineate a specific pathogenic role for 
CD14 during experimental cerebral malaria infection, showing 
a protective outcome in Plasmodium berghei–infected trans-
genic CD14 mice.9
Although differing outcomes have been reported for the 
critical role of TLRs alongside CD14, its co-receptor, in medi-
ating disease susceptibility or outcome in malaria infection,26–29 
it is abundantly clear that this promoter gene potentially has a 
significant role in disease outcome. Would CD14 promoter 
gene (rs2519190) single-nucleotide polymorphism (SNP) be a 
mediating factor in who develops severe or acute disease in 
sub-Saharan Africa? Will the hereditary variants regulate ini-
tiation of immune response thereby affecting (positively or 
negatively) phagocytosis and the inflammatory cascade follow-
ing infection as well as clinical parameters of disease? Dissecting 
the essentiality of CD14 promoter gene polymorphism in 
acute P falciparum malaria–infected patients is imperative, nec-
essary to bridge the existing knowledge gap.
Our objective is to investigate any association between 
CD14-snp159 C/T (rs2569190) gene polymorphism and sus-
ceptibility to acute malaria infection or other measures of dis-
ease severity, such as parasitemia, fever, and anemia. To do this, 
we conducted a detailed analysis of genetic diversity of CD14 
promoter gene polymorphism in an infected group versus 
uninfected controls, recruited from sub-Saharan Africa. 
Genomic DNA samples obtained from 106 P falciparum 
malaria–infected (microscopy and polymerase chain reaction 
[PCR] confirmed) patients and 227 uninfected controls from 
southwestern Nigeria were subjected to a PCR-RFLP analysis. 
We evaluated association with parasitemia, age of patients, 
fever, and anemia (packed cell volume [PCV]).
Materials and Methods
Subjects and demographics
A total of 106 patients (age range: 6 months-5 years), who pre-
sented with presumptive, acute malaria infection (initial diag-
nosis positive for P falciparum by rapid diagnostic test [RDT]) 
at St Mary Catholic Hospital, from November 2013 to 
November 2014, and whose parents/guardians provided 
informed consent were recruited from Ibadan, south-western 
Nigeria, to participate in this study. Rapid diagnostic test was 
performed with the SD Bioline histidine-rich protein 2 
(HRP-2) kit (Standard Diagnostics, Gyeonggi-do, Republic 
of Korea), with parasite species detected according to manu-
facturers instruction. Patients, recruited from same geographi-
cal area, with similar ethnic mix (Yoruba) were examined, and 
temperature reading, indicative of fever, was recorded. 
Capillary blood from a finger prick was spotted onto Whatman 
filter papers (GE Healthcare Bio-Sciences Corp, Piscataway, 
NJ, USA), after sterilizing the fingertip with an alcohol swab. 
Thin and thick blood smears were made for microscopy 
purposes, whereas anemia was determined by PCV. Genomic 
DNA was extracted from blood samples with a Qiagen Blood 
Mini Kit, according to standard protocols (Qiagen Inc., 
Valencia, CA, USA). DNA elution volume of 100 μL total was 
stored at −20°C, until further analysis. In addition, 277 
genomic DNA samples, from same geographical location and 
same ethnic mix (RDT and PCR negative for malaria infec-
tion), served as uninfected controls. This project was approved 
by the University of Ibadan/University College Hospital 
Institutional Review Committee (approval number UI/
EC/12/0279) and conducted in accordance with Helsinki 
declaration of 1975. Fever was determined by measuring the 
axillary body temperature. Anemia was determined by meas-
uring the PCV, expressed as a percentage, whereas parasite 
count was evaluated per microliter of blood by counting the 
maximum number of parasite per 200 leukocytes multiplied 
by 8000.
PCR confirmation for malaria infection
To confirm microscopy results, PCR assay targeting the 18S 
ribosomal RNA gene of Plasmodium spp, with primers, proto-
cols, and reaction setup, was conducted.31,32 Polymerase chain 
reaction was performed on a Prime G thermal cycler (Bibby 
Scientific, Staffordshire, UK) in a total volume of 25 μL and 
amplified using 1× PCR buffer (20 mM Tris-HCl [pH 8.4], 
50 mM KCl, and 1.5 mM of MgCl2), 0.125 mM of dNTPs, 
0.25 mM of each primer, and 1 U Taq DNA polymerase (New 
England Biolabs, Hitching, UK). About 5 μL of amplified 
products was loaded onto 2% agarose gels (SeaKem Agarose, 
Lonza, Rockland, ME, USA), and band size was determined 
poststaining with SYBR Green 1 gel stain (Cambrex 
Biosciences, East Rutherford, NJ, USA).
Genotyping for CD14 promoter gene (rs2569190) 
polymorphism
To assay for the SNP of the CD14 promoter gene (rs2569190), 
we used a previously published primer and protocol,33 with 
some amendments. We amplified 1 μL of genomic DNA as 
template, with conditions optimized to 25 μL of final volume, 
as described.1 About 5 μL of PCR products was examined on a 
2% ethidium bromide–stained agarose gel; positive amplifica-
tion yielded products of 561 base pairs (bp) and size estimated 
with a GeneRuler 100bp Plus DNA ladder (Thermo Fisher 
Scientific Inc, Springfield Township, NJ, USA).
RFLP assay
To determine genotypic and allelic frequencies of the polymor-
phic variants, we set up a RFLP assay using the FastDigest 
BsuRI enzyme (Thermo Scientific), following manufacturer’s 
guidelines, as previously described.34 Digested products were 
analyzed on a 3% agarose gel, and band sizes were determined, 
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as described.1 Restriction analysis was conducted by 2 investi-
gators, with 100% concordance. Homozygote wild-type vari-
ants (snp −159 C/C; rs2569190) produced bands of 204, 201, 
and 156 bp, whereas homozygote mutant variants (snp −159 
T/T; rs2569190) produced bands of 360 and 201 bp.
Statistical analysis
Tests for deviation from Hardy-Weinberg equilibrium (HWE) 
were performed, with SNPs rejected based on the recom-
mended threshold of P < .05 in control individuals.35 Differences 
between malaria and control groups were assessed by odds 
ratio. Original files were converted to an EH program format 
to resolve genotypic and allelic frequencies, as previously 
described.30
Results
We examined the genetic diversity of the CD14 gene promoter 
(−159 C/T; rs1800829) SNP that has been demonstrated to 
exhibit significant relevance within and between disease groups 
and evaluated its association with disease outcome in P falcipa-
rum malaria–infected patients. To do this, we subjected 
genomic DNA samples extracted from malaria-infected 
patients (n = 106) and control group (n = 277) to a PCR-RFLP 
assay. Genotypic frequencies at each variant were compatible 
with the HWE (P > .05). Our results show that there is a wide-
spread diversity in the genotypic frequency of the CD14 pro-
moter gene between malaria-infected and control populations, 
with this diversity more pronounced in malaria-infected 
patients but not among uninfected controls (Table 1). The 
wild-type variant (snp −159 C/C) of the CD14 promoter gene 
had a higher frequency in patients with malaria compared with 
controls (Figure 1). In fact, the mutant variant (snp −159 T/T) 
(depicting a nonsynonymous polymorphism and possibly func-
tional significance) was extensively widespread and signifi-
cantly diverse in its frequency between both groups (3.8% 
versus 22.4% for malaria-infected and control groups, respec-
tively; P = 3.32E−06). In other words, the mutant allele was less 
common among malaria-infected patients compared with 
uninfected controls. Examining the allelic frequency of this 
gene revealed a similar pattern to that for genotypic distribu-
tion, with the mutant allele significantly less frequent (Figure 
2) than the wild-type variant (23.6% versus 38.3% for malaria-
infected and uninfected controls, respectively; P = .0001).
To determine whether the CD14 gene promoter genetic 
diversity results correlate with markers of clinical disease or 
severity, we evaluated parasite load (parasites/μL of blood), 
fever (°C), anemia (PCV), and age (months) among malaria-
infected patients. We found no statistically significant differ-
ence or any association for age (mean age: 31.9 versus 
38.7 months; P = .42), fever (mean temperature: 38.4°C versus 
38.7°C; P = .70), or anemia (mean PCV: 29.4% versus 31.7%; 
P = .37) among malaria-infected patients with either the 
Table 1. Genotypic and allelic frequencies of CD14 (snp −159 C/T; rs2519190) promoter gene polymorphisms between patients with Plasmodium 
falciparum–infected malaria and healthy, uninfected controls.
POLYMORPHISM GENOTYPE MALARIA: N = 106 (%) CONTROLS: N = 277 (%) ODDS RATIO (95% CI) P vALUE
CD14 (rs2569190) C/C 60 (56.6) 127 (45.8) 1.54 (0.96–2.48) Reference
C/T 42 (39.6) 88 (31.8) 1.41 (0.86–2.30) .15
T/T  4 (3.8) 62 (22.4) 0.14 (0.04–0.38) 3.32E−06
ALLELE MALARIA: N = 212 (%) CONTROLS: N = 554 (%) ODDS RATIO (95% CI) P vALUE
CD14 (rs2569190) C 162 (76.4) 342 (61.7) 2.00 (1.38–2.94) Reference
T  50 (23.6) 212 (38.3) 0.50 (0.34–0.72) .00012
Abbreviations: C, cytosine; CD14, cluster of differentiation 14; CI, confidence interval; RDT, rapid diagnostic test; T, thymine.
Control group populations are individuals without malaria parasitemia and healthy control populations are individuals without malaria infection determined by RDT, 
microscopy, and PCR and recruited from south-western Nigeria. C/T denotes alleles at the CD14 locus. Odds ratio was calculated by Fisher 2-tailed exact test. P < .05 
was considered significant.
Figure 1. Genotypic frequency of CD14 gene promoter polymorphism 
(snp −159 C/T; rs2569190) between Plasmodium falciparum malaria–
infected patients and healthy controls. Amplified PCR products were 
digested with FastDigest BsuRI restriction endonuclease (Thermo 
Scientific, NJ, USA) and expressed on a 3% ethidium bromide–stained 
agarose gel. Wild-type variant (snp −159 C/C) produced 3 bands (204, 
201, 156 bp), whereas mutant variant (snp −159 T/T) produced 2 bands 
(360 and 201 bp) on digestion. Marker: GeneRuler 100bp Plus DNA 
ladder (Thermo Scientific). Black bars indicate patients with malaria; gray 
bars indicate uninfected controls.
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wild-type (snp −159 C/C) or mutant (snp −159 T/T) variants, 
respectively. Surprisingly, we found mean parasitemia was 
mildly significantly regulated (P = .07), based on CD14 gene 
promoter polymorphic profile (19 855 parasites/μL of blood 
versus 37 041 parasites/μL of blood versus 49 396 parasites/μL 
of blood for patients with mutant, heterozygote, and wild-type 
variants, respectively). This implies that among P falciparum 
malaria-infected patients in sub-Saharan Africa, genetic diver-
sity of the CD14 rs2569190 promoter gene is potentially a sig-
nificant factor regulating parasite load and consequently disease 
severity (Figure 3).
Discussion
Malaria is still a disease that confounds a lot of researchers 
globally and the millions who fall sick to this infection con-
stantly, especially considering the possibility of multiple infec-
tions in a single year. Despite the intensified efforts toward 
designing a vaccine or new therapeutic regimen to replenish 
the stock of available antimalarials, thereby reducing the 
scourge of disease due to resistant parasites, there is a further 
need for deconvoluting the various factors contributing to the 
diversity in disease severity or susceptibility among endemic 
populations. One of such potential factors is CD14, a leucine-
rich repeat surface protein linked to macrophage TLRs that 
functions as a receptor for bacteria lipopolysaccharide and 
microbial ligand recognition,14,18 as well as host response to 
viral and fungal infections.36,37 Its polymorphism has been 
shown to be a major regulator of innate immune response,10 
and its demonstrated expression in the brain is a critical factor 
in the development of cerebral malaria.9 Significantly, it has 
been shown that CD14 genetic factors that affect differential 
expression of downstream genes would potentially have func-
tional imperative in the immune response to infectious patho-
gens or immunological diseases.10 To this end and as part of 
our ongoing work on immune regulatory patterns contributing 
to disease diversity and severity, we set out to determine the 
role, if any, of the genetic diversity of CD14 gene promoter 
polymorphism (snp −159 C/T; rs2519190) on markers of clini-
cal disease or severity among and between P falciparum 
malaria–infected patients from sub-Saharan Africa. We found 
that the polymorphism was equally distributed, showing no 
deviations from HWE (P > .05) within malaria-infected and 
control groups, implying our result is not due to selection pres-
sure, that can be attributed to the disease.
Even though there are a number of publications referencing 
CD14 and its regulatory or contributory role in several condi-
tions and diseases, including allergy, just a handful is directly 
related to malaria. A signature publication on murine cerebral 
malaria showed that deletion of the CD14 gene confers protec-
tion against disease and a negative effect on parasite growth in 
transgenic mice challenged with P berghei ANKA9 and recom-
mended that this observation be elucidated in human infec-
tions. Our result among P falciparum malaria–infected 
individuals confirm this finding, whereby the wild-type variant 
of CD14 gene promoter polymorphism had the highest 
Figure 2. Allelic frequency of CD14 gene promoter polymorphism (snp 
−159 C/T; rs2569190) between Plasmodium falciparum malaria–infected 
patients and healthy controls. Amplified PCR products were digested with 
FastDigest BsuRI restriction endonuclease (Thermo Scientific, NJ, USA) 
and expressed on a 3% ethidium bromide–stained agarose gel. Black 
bars indicate patients with malaria; gray bars indicate uninfected controls.
Figure 3. Mean parasite distribution between patients with malaria with 
either (A) wild-type (−159 C/C) or mutant (−159 T/T) variants and (B) 
wild-type (−159 C/C+C/T) versus mutant (−159 T/T) variants of the CD14 
gene promoter polymorphism (snp −159 C/T; rs2569190).
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statistically significant genotypic and allelic frequencies among 
patients with malaria when compared with uninfected controls. 
In addition, the mutant variant was less frequent in malaria-
infected patients compared with the higher frequencies in 
uninfected controls. This observation has significant implica-
tions for disease susceptibility among endemic populations and 
could potentially clarify clinical differences or degrees of dis-
ease severity in subcontinental population groups across sub-
Saharan Africa. Examining this finding among Plasmodium 
vivax malaria–infected groups within and outside sub-Saharan 
Africa would be an added benefit of this present report.
Oakley et al also reported on the beneficial role of CD14 in 
regulating parasitemia among CD14 transgenic and wild-type 
P berghei ANKA–infected mice, with the transgenics showing 
2-fold reduction in parasitemia postinfection as well as longer 
survival rate. This is a very interesting and significant finding 
superbly confirmed by our result in human infection. We found 
the highest mean parasitemia among malaria-infected indi-
viduals with the CD14 gene promoter wild-type variant and a 
2.5-fold reduction (mildly significant) in mean parasitemia 
among individuals with the mutant variant. This is very impor-
tant considering the significance of immune regulatory mark-
ers in initiating immune response to antigenic stimuli. Despite 
the fact that Togbe et al38 saw no conferred protection by the 
loss of the CD14 gene in murine cerebral malaria, this present 
finding clarifies possible differences between human and 
murine infections, and potential benefit of the CD14 gene in 
human P falciparum infection, not seen in animals (multiple 
backcrosses, differing genetic background, parasite lines/
clones), which are completely different from field infections.
In addition, although Wenisch et  al25 reported that they 
found no relationship between soluble CD14 and markers of 
disease severity in malaria infection, our present result states 
otherwise, based on genetic diversity analysis. Our results qual-
itatively delineate the potential reasons for the results obtained 
by Wenisch et al. This is an excellent study that should move 
this field further, especially among malaria-infected individuals 
from differing ethnic or endemic backgrounds or while exam-
ining severity of infection among nonimmune travelers from 
nonendemic regions. We recommend further studies with 
larger sample sizes and different population groups across sub-
Saharan Africa.
The results in this study further confirm reports that 
CD14 polymorphism potentiates a TH1 differentiation and 
subsequent IFN-γ response leading to reduced malaria para-
sitemia. We believe that a variant CD14 would drive a defi-
cient response leading to an immune cascade that could 
potentially make disease worse, leading to complications, 
compared with a normal immune response, in which infec-
tion can be adequately managed or controlled. Such compli-
cations could potentially include high-circulating immune 
complex levels,1 extensive parasite diversity,39 incomplete 
clearance of parasites posttreatment and potential for recru-
descence,2 or possibly development of drug-resistant strains. 
To this end, it is imperative that our results be extended by 
analyzing pro-inflammatory biomarkers in serum assays 
from similar patient groups as well as patients with cerebral 
or severe malaria, in addition to clarifying any contributory 
role TLR polymorphisms may play in regulating disease 
markers. In addition, we advocate strengthening awareness 
and understanding of CD14 regulatory effects on innate 
immune response, especially with malaria infection in sub-
Saharan Africa, and potential to exacerbate disease outcome 
among infected individuals carrying the CD14 promoter 
gene mutant variant. We conclude that P falciparum malaria 
severity in sub-Saharan Africa is significantly regulated by 
CD14 promoter gene (snp −159 C/T; rs2569190) polymor-
phism, in addition to its importance for clinical disease, 
markers of severity, and immune response. How this diversity 
affects clinical presentation or disease severity between sub-
regional or intercontinental population groups deserves fur-
ther elucidation.
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